A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease-Reference-Cited by-同舟云学术

A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease

Published:2021-06-01 Issue:6 Volume:175 Page:617
ISSN:2168-6203
Container-title:JAMA Pediatrics
language:en
Short-container-title:JAMA Pediatr

Author:

DeMartino Patrick¹,Haag Meredith B.¹,Hersh Alyssa R.²,Caughey Aaron B.²,Roth Joshua A.³

Affiliation:

1. Division of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Doernbecher Children’s Hospital, Portland

2. Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland

3. University of Washington School of Pharmacy, Fred Hutchinson Institute for Cancer Outcomes Research, Seattle

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Link

https://jamanetwork.com/journals/jamapediatrics/articlepdf/2777594/jamapediatrics_demartino_2021_oi_200108_1622130411.06068.pdf

Reference33 articles.

1. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system.;Quinn;Value Health,2019

2. Alternative state-level financing for hepatitis C treatment—the “Netflix model”.;Trusheim;JAMA,2018

3. Can outcomes-based pharmaceutical contracts reduce drug prices in the US? a mixed methods assessment.;Seeley;J Law Med Ethics,2018

4. Health-related quality of life in sickle cell disease: past, present, and future.;Panepinto;Pediatr Blood Cancer,2012

5. Hydroxyurea and sickle cell anemia: effect on quality of life.;Ballas;Health Qual Life Outcomes,2006

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A budget impact analysis of gene therapy for sickle cell disease: an updated analysis;Blood Advances;2024-08-30

2. Haploidentical Stem Cell Transplants in Children With Sickle Cell Disease: A Single Center Real-world Experience;Journal of Pediatric Hematology/Oncology;2024-08-26

3. Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease;Clinical Drug Investigation;2024-08

4. A Winding Road to Health Care Equity in Sickle Cell Disease;Clinics in Laboratory Medicine;2024-08

5. Gene therapies on the horizon for sickle cell disease: a clinician’s perspective;Expert Review of Hematology;2024-07-31